Insider buying last 90 days
No open-market insider purchases were filed for COR in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 16 close
Cencora closed at $356.94 on 16 November 2026, -0.6% on the day. The price sits above both the 50-day ($327.68) and 200-day ($316.70) moving averages, inside a 52-week range of $244.82 to $377.54. The GekkoIndex reads 49.6, in the Neutral zone, down 3.3 points over five sessions. Gekko Fair Value is $545.35, so the price is 34.5% below it.
The next earnings report is due on 3 February 2027, 78 days away (before open). Over the last 8 reports the company beat the earnings estimate 8 times, with an average move of 4.9% across the report. Smart-money activity over the last 90 days includes 1 Congress purchase and 0 sales. Seasonally, the next 20 trading days from this point averaged 0% over the last 5 years, rising in 2 of them.
9 firms rate the stock: 7 buy, 2 hold and 0 sell, with a consensus target of $381.25. A typical daily move is about 2.9%, and a typical 20-day move about 4.7%. On the swing-trade checklist, 4 items read supportive and 0 read as a headwind.
A plain summary of the figures as of the Nov 16, 2026 close.
Cencora scores 4 supportive, 1 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed1 headwind
Above 50 and 200-day
Close $356.94 is above the 50-day ($327.68) and 200-day ($316.70) averages, and the 50-day is above the 200-day.
See the chart49.6, Neutral
Reading 49.6 is in the Neutral zone.
See the GekkoIndex34.3% below
Price is 34.3% below Gekko Fair Value (more than 5% below).
See fair valueLeans bullish
Last 90 days: Congress 1 buy / 0 sales.
See smart moneyReports in 78 days
Next report Feb 3, 2027, 78 days away — outside a typical 20-trading-day hold.
See earnings−0.7% on average
From this point in the calendar, the next 20 trading days averaged −0.7% over 5 years, rising in 2 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Cencora closed at $356.94 on Nov 16, 2026, −2.3% over the past year, inside a 52-week range of $244.82 to $377.54.
Use the left and right arrow keys to read daily values.
Put COR on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Cencora sources and distributes pharmaceutical products across the United States and international markets. Through its U.S. Healthcare Solutions segment, it supplies generic and injectable medications, over-the-counter health items, and home healthcare equipment, along with specialized products such as plasma, blood derivatives, and vaccines. The company is also known for its work in animal health, offering pharmaceuticals, vaccines, parasiticides, diagnostics, and feed ingredients for companion and production animals.
Cencora's customers include acute care hospitals, health systems, retail and mail-order pharmacies, medical clinics, oncologists, dialysis clinics, and other healthcare providers. Beyond product supply, it provides pharmacy management, staffing, and consulting services, builds supply management software, handles packaging for institutional and retail healthcare settings, and supports clinical trials, post-market approval, and commercialization for biotechnology and pharmaceutical manufacturers, including data analytics and outcomes research. Its International Healthcare Solutions division handles global pharmaceutical wholesale operations, commercialization support, and logistics for the biopharmaceutical sector, reaching pharmacies, doctors, health centers, and hospitals abroad.
The company traces back to 1871 and was previously named AmerisourceBergen Corporation before taking the name Cencora in August 2023. It is headquartered in Conshohocken, Pennsylvania, and its shares are listed on the NYSE under the ticker COR.
Cencora’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 49.6, in the Neutral zone, down 3.3 points over five sessions.
Down 3.3 points over five sessions.
Reading for Nov 16, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 27 | −0.5% | +4.6% | ||
| Accumulation | 181 | +0.6% | +2.5% | ||
| Neutral (current zone) | 433 | +0.5% | +0.9% | ||
| Distribution | 64 | −0.6% | +0.3% | ||
| Selling | 2 | Too few readings yet | |||
Average COR share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Cencora trades 34.3% below Gekko Fair Value of $543.28, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Cencora shares are worth, recalculated every trading day.
$543.28
Gekko Fair Value, Nov 17, 2026
34.3% Undervalued
At the end of Aug 2026 the price was 31.7% below the estimate.
No open-market insider purchases were filed for Cencora, and members of Congress disclosed 1 purchase and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for COR in the last 90 days.
From Form 4 filings, dated to when each was filed.
1trade disclosed: 1 purchase and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Ro Khanna House, CA, purchase | $1,001 - $15,000 | Oct 9 traded Sep 4 |
From congressional disclosures, which report amounts as ranges.
Cencora has been buying back its own shares.
From company filings.
0of the funds Gekko tracks hold COR.
Cencora reports on Feb 3, 2027, before the open (78 days away), and beat the EPS estimate in 8 of its last 8 reports.
Feb 3, 2027
Expected before the open, 78 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Nov 4, 2026 | $4.66 est $4.58 | $88.35B est $87.95B | −0.2% |
| Aug 5, 2026 | $4.48 est $4.37 | $84.75B est $84.31B | +6.1% |
| May 6, 2026 | $4.75 est $4.73 | $78.36B est $81.09B | −16.4% |
| Feb 4, 2026 | $4.08 est $4.05 | $85.93B est $86.06B | −2.7% |
| Nov 5, 2025 | $3.84 est $3.79 | $83.73B est $83.46B | +4.6% |
| Aug 6, 2025 | $4.00 est $3.85 | $80.66B est $80.09B | −4.8% |
| May 7, 2025 | $4.42 est $4.11 | $75.45B est $75.68B | −2.4% |
| Feb 5, 2025 | $3.73 est $3.52 | $81.49B est $78.31B | −2.2% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Cencora is $382.42, +7.1% from the last close, from 9 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 9 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 10 | Bank of America Securities | $360 | +0.9% |
| Nov 10 | J.P. Morgan | $413 | +15.7% |
| Nov 5 | RBC Capital | $330 | −7.5% |
| Nov 5 | Robert W. Baird | $405 | +13.5% |
| Nov 5 | Bank of America Securities | $360 | +0.9% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 17, Cencora averaged −0.7% across the last 5 years, rising in 2 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +2.4% | 4 of 5 |
| Next 10 trading days | +1.4% | 3 of 5 |
| Next 15 trading days | −0.4% | 3 of 5 |
| Next 20 trading days | −0.7% | 2 of 5 |
| Next 30 trading days | +0.8% | 3 of 5 |
For scale, COR’s typical 20-trading-day move in either direction is about 4.7%.
Cencora’s market cap is $68.11B, with a P/E ratio of 20 and revenue of $337.4B over the last twelve months.
Coverage of Cencora this week reads neutral: 1 positive, 11 neutral and 1 negative headlines.
Cencora’s 3 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| MCKMcKesson | Distribution | 2.6% above |
| CAHCardinal Health | Distribution | 31.0% below |
| HSICHenry Schein | Neutral | 5.3% above |
A peer links to its own page where one exists.
Cencora’s market cap is $68.11B at the Nov 16, 2026 close of $356.94, with 190.8M shares outstanding. The shares trade on a P/E ratio of 20.
The consensus analyst 12-month price target for Cencora is $382.42, +7.1% from the last close. Of the 9 firms that rated the stock in the last 90 days, 7 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Cencora is undervalued: the Nov 16, 2026 close of $356.94 is 34.3% below Gekko Fair Value of $543.28. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Cencora is expected to report on Feb 3, 2027, before the market opens (78 days away). Analysts expect earnings of $4.53 per share on revenue of $90.46B. Cencora beat the earnings estimate in 8 of its last 8 reports, moving 4.9% on average across the report.
Cencora’s 52-week high is $377.54 and its 52-week low is $244.82; it closed at $356.94 on Nov 16, 2026, −2.3% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (trend, fair value, smart money and earnings risk), 1 as mixed (gekkoindex) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,476 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.